Divestment of Thirona Retina BV to continue focus on pulmonary diseases and expanding within the interventional pulmonology space

Blackford and Thirona announce a commercial partnership to bring the LungQ™ solution to healthcare professionals via the Blackford Platform.

Voiant and Thirona have entered a global commercial partnership to provide full scope integral services for clinical trials (with AI-powered lung image analysis), building further on several years of a fruitful cooperation.

Thirona has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the latest update of its AI-based clinical software LungQ™ (v3.0.0)

Thirona is thrilled to have secured €7,5 Million ($8 Million) of financing from HERAN Partners, Borski Fund and the EIC.

Thirona’s AI-Based LungQ™AVX Reveals New Potential for Treatment of Vascular Diseases.